Receive alerts
Market Cap:
$162.72 m
52 weeks high
52 weeks low

Filter by article type

Viewing results 1-25 of 148


VolitionRx balance sheet strengthens in second quarter with cash increasing significantly

The Belgium-based firm said its cash and cash equivalents as of June 30, 2019 totaled $18.5 million compared to $13.4 million as of the end of 2018...

on 08/12/2019

VolitionRx forms new Texas veterinary subsidiary, taps animal health expert Nathan Dewsbury to head it

Volition's NuQ diagnostic blood tests pinpoints irregular levels of nucleosomes in the blood, which indicate cancer...

on 08/08/2019

VolitionRX brings its Nu.Q cancer-screening platform to China

The company is partnering with Shanghai Fosun Long March Medical Science Co Ltd, a manufacturer of diagnostic and laboratory instruments on a lung cancer study...

on 07/18/2019

VolitionRx Limited awarded an additional $1.4 million in non-dilutive funding

The grant will support a specific project to be conducted in collaboration with GIGA at the University of Liege, Belgium...

on 07/10/2019

VolitionRx’s Nu.Q cancer-screening blood tests could replace colonoscopies, biopsies

Belgium-based company’s Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect ovarian disease endometriosis ...

on 06/21/2019

VolitionRx boosts cash reserves in 1Q

VolitionRx ended its first-quarter with $16.2 million in cash and cash equivalents...

on 05/08/2019

VolitionRx updates investors on Nu.Q technology progress, new paths to revenue at NYSE event

In a push to generate revenue, the Isnes, Belgium-based company aims to have the first Nu.Q Vet product on the market in the US in 2020...

on 04/10/2019

VolitionRx subsidiary inks pact with Texas A&M University to develop Nu.Q veterinary diagnostic blood tests

The company aims to have the first Nu.Q Vet product on the market in the US in 2020...

on 04/09/2019

VolitionRx expands its lung cancer detection clinical trial program using its novel Nu.Q blood test

Belgian Volition SPRL ropes in the National Taiwan University to evaluate its Nu.Q technology platform through a study of 1,200 subjects, a majority of them with lung cancer...

on 04/03/2019

VolitionRx strengthens balance sheet in 2018 as Nu.Q blood test notches further advances in cancer-detection trials

CEO Cameron Reynolds says further development of Volition’s Nu.Q Capture and Nu.Q Vet products will help "drive early revenue"...

on 03/14/2019

VolitionRx reports several highlights in 2018 and eyes key milestones going into 2019

The company is bolstering its intellectual property rights by securing additional patents...

on 11/07/2018

VolitionRx's revolutionary Nu.Q blood tests could change the future of cancer screening

The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies...

on 10/25/2018

VolitionRx moves into veterinary medicine after encouraging study results

A study showed that nucleosomes in the blood – which are evaluated for the presence of cancer by the company’s NuQ diagnostic blood tests – can also be detected in dogs...

on 10/04/2018

VolitionRx's Nu.Q blood-based diagnostic tests offer great potential, says Oppenheimer analyst

Analyst Mark Breidenbach's valuation is based primarily on Nu.Q's market opportunity for colorectal cancer screening in the US and EU...

on 08/15/2018

VolitionRx expects its Nu.Q blood-based test kits to generate new revenue in coming quarter

As part of a sales agreement for an array of research-use-only kits, the Belgium-based company's Nu.Q Total assay kit is now for sale...

on 08/13/2018

VolitionRx unveils data showing its Nu.Q assays detect aggressive prostate cancer in men with 94% accuracy

VolitionRx CEO Cameron Reynolds said that if the results are validated in larger trials, they would present a 'significant new market opportunity'...

on 08/13/2018

VolitionRx completes blood sample collection as part of joint University of Oxford endometriosis study

The company will begin screening the samples using its Nu.Q. Assay kits and expects to report preliminary data in coming months...

on 08/09/2018

VolitionRx enters into US$9mln private placement

The life sciences company said the PIPE deal would fund key product development, clinical studies and product commercialization ...

on 08/08/2018